Le Qu;Jin Ding;Cheng Chen;Zhen Jie Wu;Bing Liu;Yi Gao;Wei Chen;Feng Liu;Wen Sun;Xiao Feng Li;Xue Wang;Yue Wang;Zhen Yu Xu;Li Gao;Qing Yang;Bin Xu;Yao Ming Li;Zi Yu Fang;Zhi Peng Xu;Yi Bao;Deng Shuang Wu;Xiong Miao;Hai Yang Sun;颖浩 孙;红阳 王;Lin Hui Wang
Second Military Medical University;Nanjing University;Zhejiang University
发表时间:2016-5-9
期 刊:Cancer Cell
语 言:English
U R L: http://www.scopus.com/inward/record.url?scp=84963959740&partnerID=8YFLogxK
Sunitinib resistance is a major challenge for advanced renal cell carcinoma (RCC). Understanding the underlying mechanisms and developing effective strategies against sunitinib resistance are highly desired in the clinic. Here we identified an lncRNA, named lncARSR (lncRNA Activated in RCC with Sunitinib Resistance), which correlated with clinically poor sunitinib response. lncARSR promoted sunitinib resistance via competitively binding miR-34/miR-449 to facilitate AXL and c-MET expression in RCC cells. Furthermore, bioactive lncARSR could be incorporated into exosomes and transmitted to sensitive cells, thus disseminating sunitinib resistance. Treatment of sunitinib-resistant RCC with locked nucleic acids targeting lncARSR or an AXL/c-MET inhibitor restored sunitinib response. Therefore, lncARSR may serve as a predictor and a potential therapeutic target for sunitinib resistance.
Scopus度量
年份 | CiteScore | SJR | SNIP |
---|---|---|---|
1996 | |||
1997 | |||
1998 | |||
1999 | |||
2000 | |||
2001 | |||
2002 | |||
2003 | 9.46 | 2.445 | |
2004 | 11.168 | 2.781 | |
2005 | 11.785 | 2.723 | |
2006 | 12.358 | 3.276 | |
2007 | 12.992 | 3.742 | |
2008 | 15.652 | 4.408 | |
2009 | 15.159 | 4.558 | |
2010 | 16.468 | 4.669 | |
2011 | 40 | 16.203 | 4.749 |
2012 | 42.4 | 16.267 | 4.92 |
2013 | 43.9 | 17.638 | 4.933 |
2014 | 40.4 | 14.883 | 4.632 |
2015 | 41.7 | 13.74 | 4.934 |
2016 | 40.3 | 13.509 | 5.089 |
2017 | 44.3 | 12.7 | 4.877 |
2018 | 37.8 | 11.741 | 4.691 |
2019 | 40.7 | 11.909 | 5.086 |
2020 | 39.1 | ||
2021 |
相似文献推荐